Targeted biology
We focus on the underlying drivers of chronic inflammatory skin conditions — not just their surface symptoms.
Precision delivery for the skin's toughest diseases.
Drosia BioPharma is advancing a novel dermal delivery platform designed to bring targeted biologic therapy directly to inflammatory skin disease.
What we do
Rethinking how skin disease is treated.
Precision delivery
A dermal delivery platform engineered to place therapy where it is needed, with patient comfort in mind.
Disciplined development
A capital-efficient path built on validated science and a clear regulatory strategy toward the clinic.
“Our mission is to make effective, well-tolerated treatment possible for the millions living with chronic inflammatory skin disease.”
About
A focused company with a clear thesis.
Drosia BioPharma is a London-based, early-stage biopharmaceutical company. We are building around a single, focused thesis: that precision dermal delivery can unlock meaningful new options for patients with inflammatory skin disease.
Founded and led by a biopharma executive with a track record of taking biologics from early development through approval and commercialisation, Drosia is advancing its flagship programme towards the clinic with support from expert clinical, regulatory and IP advisers, internationally recognised KOLs and world-class CRO partners, while selectively partnering with organisations that share its vision.
Get in touch
Let's talk.
For partnering, investment and general enquiries. We respond to every message.